Conference Preview: Diabetes Technology Meeting (DTM) 2015 – October 6, 2015

October 22-24, 2015 – Bethesda North Marriott Hotel & Conference Center – Bethesda, MD

Conference Website

Conference Schedule


From October 22-24, our team will travel to Bethesda, MD for the Diabetes Technology Society’s 15th Annual Diabetes Technology Meeting, hosted at the Bethesda North Marriott Hotel & Conference Center. This year’s meeting features an outstanding series of pre-conference workshops (October 22), headlined by presentations on reimbursement, DIY technology (including Bigfoot Biomedical’s Bryan Mazlish and FDA’s Dr. Courtney Lias), big data, and glucose measurement and insulin dosing errors.

The conference will begin in earnest on Friday morning (October 23) with a keynote presentation on cybersecurity from the White House, followed by an entire session on the topic. To date this issue has provoked a lot of unnecessary noise, so we’ll be interested to see what key takeaways emerge. The rest of the day looks very strong, including: (i) a provocative session on how good CGM must be to replace SMBG (FDA’s Dr. Courtney Lias will moderate, and powerhouse type 1 FDA rep Dr. Alain Silk will speak); (ii) a debate on biological vs. closed-loop approaches to treating type 1 (how about “BOTH?”); (iii) a debate on the value of blinded vs. real-time CGM; (iv) a discussion of the limitations in artificial pancreas development; and (v) new developments in pump therapy.

Saturday also has some standout sessions, headlined by a series of CGM updates from Medtronic, Dexcom, Abbott, Roche, Senseonics, GlySens, and Arkray. Weekend attendees will also hear a can’t-miss session on using hypoglycemia as a clinical trial endpoint (an all-star lineup there: Drs. Aaron Kowalski, Abbott’s Tim Dunn, Boris Kovatchev, Zan Fleming, and John Pickup). DTM will continue its expansion beyond traditional hardware, with sessions on mobile apps (FDA’s Associate Director of Digital Health, Dr. Bakul Patel!), social media, novel insulins, microbiome, and even amputation.

There is a slightly new format this year, as Friday afternoon and Saturday morning are divided into parallel “Scientific” and “Clinical” tracks. The change is a testament to the diverse audience (clinicians, researchers, industry), and also speaks to how much the conference has grown over time.

We’re also glad to see another strong FDA commitment to engage in dialogue at DTM – by our count, the FDA device division will present or moderate in five sessions. That is absolutely unprecedented and also speaks to Dr. Klonoff’s strong relationships with the Agency. We hope the drug side of FDA takes note!

Below, we have enclosed a preview of the conference, organizing the highlights of the sessions by day. Online registration for the meeting is available until October 20, though registration for the pre-conference workshops is separate. We hope to see some of you in Bethesda!

Thursday, October 22 (Pre-Conference Day)

  • (8:oo am -11:25 am) Workshop A: Business Opportunities in Diabetes Technology. The pre-conference events will open with two concurrent workshops, each consisting of two “panel” sessions (see below).
    • (8:00 am – 9:30 am) Panel 1: Investing in Diabetes Technology. Dr. Bruce Quinn (FaegreBD Consulting, Washington DC) will open by discussing reimbursement models for current technology. We expect he will speak about the complexity of the current healthcare system and the challenges it poses for reimbursement – a topic he addressed in depth at the DTM in 2012. Mr. John Ryan (Onset Ventures, Menlo Park, CA) will follow with a presentation on what venture capitalists look for when seeking out new investments (Diabetes: a big and growing market opportunity, outcomes that are not improving, system waste, and significant morbidity and mortality). It will also be fascinating to hear BD’s Dr. James Petisce talk about “what a large corporate partner looks for” – indeed, we imagine companies like BD are getting pitched new technologies and apps weekly.
    • (9:55 am – 11:25 am) Panel 2: Reimbursement. Reimbursement expert Mr. James Scott  (CEO, Applied Policy, Alexandria, VA) will present his thoughts on competitive bidding in a new category: insulin pumps. This Medicare program has devastated BGM, and we hope Mr. Scott can bring insights about alternatives to this system and lessons that can be learned and applied to pumps. His talk at DTM 2014 was incredibly insightful (Twitter summary: “the competitive bidding program is unsustainable”). Ms. Mary Ann Hodorowicz (Mary Ann Hodorowicz Consulting, LLC, Palos Heights, IL) and The Endocrine Society’s Ms. Meredith Dyer will follow with a discussion of CGM reimbursement in the US. They will most surely talk about the need to expand coverage to Medicare, but we hope to hear details on private coverage of CGM – what are patients with a major payer spending out-of-pocket to use CGM? How much is that hampering uptake? What impact will pharmacy distribution have? Dr. Paul Radensky (McDermott Will & Emery LLP, Washington DC) will also share his take on the reimbursement landscape, likely echoing his comments from ADA 2015 (JDRF’s Artificial Pancreas evening): support the benefits of a new technology with clear data.
  •  (8:00 am – 11:15 am) Workshop B: New Treatment Paradigms
    •  (8:00 am – 9:30 am) Panel 1: Do it Yourself. Boy are we excited to hear the FDA’s Dr. Courtney Lias on do-it-yourself diabetes technology. Recent patient grassroots efforts (Nightscout, #DIYPS, Bigfoot) have made this an increasingly pertinent topic, and we wonder where the FDA will exercise its regulatory authority. At what point does an artificial pancreas built in my own home become a regulated product? Mr. Bryan Mazlish – co-founder of Bigfoot Biomedical – will end the panel with a presentation on this very topic. We can’t imagine a better candidate and hope to hear an update on Bigfoot’s closed-loop progress. As a reminder, the company has moved quickly since our initial interview in February, raising two rounds of funding ($4.6 million in July, $3.5 million in May), acquiring Asante’s assets, and signing a CGM development agreement with Dexcom.
    • (9:55 am – 11:25 am) Panel 2: Big Data and Precision Medicine for Diabetes. Dr. Rodney Hayward’s (University of Michigan) talk title sums up the foundation of this session: “Diabetes Care Desperately Needs Precision Medicine.” The big question is how to do it – what data is critical, and how should it be collected, aggregated, and made useful? Dr. William Riley (NIH, Bethesda, MD) will discuss the use of mobile technologies to collect such data, while Janssen’s Dr. Robert Cuddihy will assess whether big data, genomics, and digital health tracking are “overpromised hype” or an “impending new era.” That should be thought provoking indeed, especially as J&J now has Invokana, its diabetes device business (LifeScan, Animas, and Calibra’s Finesse), and even some work in digital wellness through the gorgeously designed (and well-reviewed) 7-Minute Workout app.
  • (12:25 pm – 3:50 pm) Workshop C: Metrics of Glucose Measurements Errors and Insulin Dosing Errors
    • (12:25 pm – 1:55 pm) Panel 1: Metrics of BGM & CGM Accuracy. Dr. David Rodbard will open the session by discussing the accuracy and precision of both BGM and CGM. Dr. Luigi Del Re (Johannes Kepler University Linz, Austria) will follow by discussing whether MARD conveys the real performance of CGM devices, setting the stage for Roche’s Dr. Rolf Hinzmann to discuss the limitations of BGM and CGM accuracy metrics. [At DTM 2014, Dr. Hinzmann spoke passionately on the need for greater surveillance of BGMs, expressing concern that manufacturers are not consistently fulfilling quality standards.] UVA’s Dr. Marc Breton will conclude with the clinical impact of poorly performing BGMs. These are all very nuanced academic discussions – we wonder how they will translate to the day-to-day patient experience of using devices, and in turn, the critical product design choices. If MARD doesn’t capture CGM performance very well, what should be used instead (error grids?), and how will that decision change anything about product design or R&D priorities?
    • (2:20 pm – 3:50 pm) Panel 2: How to Avoid Insulin Dosing Errors. The FDA’s Dr. Patricia Beaston will moderate this discussion on insulin dosing errors, an area the Agency clearly has great interest in (e.g., the November 2014 workshop on bolus calculators). Dr. Tim Heise (Profil GmbH, Neuss, Germany) will speak on the variability of insulin absorption, while Dr. Eda Cengiz (Yale School of Medicine, New Haven, CT) will complement with thoughts on insulin dosing errors and unexpected insulin absorption (inaccurate carb counting and infusion sets are two big ones). CDC’s Dr. Hubert Vesper will address “reference systems” to improve testing accuracy, which presumably means YSI though we’re not sure. The astute Dr. Barry Ginsberg (Diabetes Technology Consultants, Wyckoff, NJ) will end with a talk on interfering substances. His wider-ranging talk on this topic at Clinical DTM 2010 estimated that the average error in selecting a final insulin dose is roughly 27%, and error from blood glucose meters is relatively minor compared to other big errors (carb counting and variable insulin absorption are the big ones). We’ll be interested to compare notes and see if his views have changed in the past five years, particularly as sensors have gotten miles better (and now factory calibrated with Abbott’s FreeStyle Libre).
  • (12:25 pm – 3:50 pm) Workshop D: A Reassessment of Markers of Glycemia
    • (12:25 pm – 1:55 pm) Panel 1: New Developments in Hemoglobin A1C. Algorithm maestro Dr. Boris Kovatchev (UVA, Charlottesville, VA) will discuss “Estimated A1c,” presumably reviewing the equation that was incorporated into Sanofi’s MyStar Extra meter. A provocative talk from Dr. James Anderson (PTS Diagnostics, Indianapolis, IN) will address the value of home A1c testing, a topic we have not seen much discussion on. Bayer sold its A1cNow business to Chek Diagnostics (formerly Polymer Technology Systems) in December 2013, presumably because sales were not very strong. Accuracy, high cost per test, and clinical utility are big questions for home A1c testing – can these kits offer a cost-effective, clinical advantage over an SMBG average? For which patients? Do cheaper sensors (e.g., Abbott, Dexcom/Google) negate the value of home A1c testing? Other talks in this session will delve into the limitations of A1c as a metric, a topic Dr. Irl Hirsch most recently addressed at Keystone 2015.
    • (2:20 pm – 3:50 pm) Panel 2: Novel Markers. Medtronic Diabetes’ Dr. Robert Vigersky will open this session with a presentation on a composite measure for evaluating diabetes therapies. He gave a similar talk at this year’s Clinical Diabetes Technology Meeting, emphasizing the need for approaches that score therapies according to A1c reductions, hypoglycemia, and weight instead of A1c alone. Other presentations will address the topic of service dogs for detecting hypoglycemia and the detection of hypoglycemia using EEG.

Friday, October 23

  • (8:00 am – 8:25 am) Session 1: Welcome & Keynote Presentation. We are very excited to hear White House Director of Cybersecurity and Technology Mr. Daniel Prieto’s keynote presentation on cybersecurity in the medical device industry. This is a timely topic as connected diabetes devices and apps are becoming more common, and an even bigger issue once closed-loop systems become a reality (an algorithm automatically infusing insulin, potentially running on a smartphone). The challenge is the safety vs. product experience balance – the most secure medical device ever might also be clunky and hard to use. Where should industry and FDA draw the line?  
  • (8:25 am – 10:10 am) Session 2: DTSec (DTS Cybersecurity Standard for Connected Diabetes Devices project). We believe that this session will introduce the Diabetes Technology Society’s “cybersecurity standard” for diabetes devices (first introduced by Dr. David Klonoff at ATTD 2015). According to Dr. Klonoff, the need for such a standard grew out of conversations with the FDA, stemming both from concerns regarding intentional (i.e., grassroots efforts to access data) and malicious efforts to hack devices. DTS began by forming a steering committee to discuss what such a cybersecurity standard would look like, though a timeline for additional activities has not been provided. Dr. Bryan Cunningham (Levy LLP, Los Angeles, CA) will provide an introduction to the safety issues associated with new diabetes devices that communicate wirelessly with smartphones, the cloud, and each other. A panel discussion on this topic will follow including: Mr. Cunningham, Dr. Barry Ginsberg (Diabetes Technology Consultants, Wyckoff, NJ), Mr. David Kleidermacher (BlackBerry Limited, Santa Barbara, CA), and Ms. Margie Zuk (The MITRE Corporation, Boston, MA).
    • Our biggest concern with this program is the potential noise factor – DTS made a big deal in 2013 (May and September) with its BGM accuracy meetings, but nothing has come out of the proposed surveillance program. Cybersecurity is an important issue for patient safety, but is this standard even needed, and is DTS the best organization to spearhead it? Don’t companies adhere to cybersecurity standards as part of the FDA submission process? This has all been very time consuming to boot for the field and we don’t see progress yet.
  • (10:35 am – 11:45 am) Session 3: How Good Does CGM Need to be for a Primary Indication to Replace SMBG? This provocatively titled session already figures to be a highlight of DTM Day #2 – we can’t wait! The FDA’s Dr. Alain Silk (who also has type 1) will kick things off with the Agency’s perspective on the non-adjunctive use of CGM – we loved his open-minded talk at the November FDA workshop on bolus calculators and hope to hear similar honesty later this month. Dr. Marc Breton will then speak from a mathematical perspective, presumably discussing UVA’s recent modeling paper (Kovatchev et al., DT&T 2015) on this topic – the paper concludes that an MARD <10% makes CGM feasible for insulin-dosing decisions. The very smart Dr. Jessica Castle of OHSU will talk future directions for non-adjunctive use of CGM, potentially addressing the artificial pancreas.
    • Per Dexcom’s 2Q15 call, an insulin-dosing label claim is expected sometime in 2016 in the US; it is not clear what Dexcom has specifically worked out with the FDA, though it is presumably a combination of pre- and post-market data. As a reminder, the newly approved EU label for Dexcom’s G5 has a replacement claim, as does Abbott’s factory-calibrated FreeStyle Libre. Abbott has never given US timing on a consumer version of FreeStyle Libre (the Pro version is under review), though a replacement claim is among the key gating factors for getting it through FDA.
  • (1:10 pm – 2:30 pm) Scientific 4: Best Approach to Type 1 Diabetes: Biological or Bioengineered? This fascinating debate will pit UCSF’s Dr. Matthias Hebrok against Cambridge’s Dr. Roman Hovorka to discuss biological vs. mechanical approaches to type 1 diabetes. We do not think this is actually a question of “or”; it’s really “and” coupled with timing. Artificial pancreas systems provide a near-term option to make daily diabetes management easier, while biological approaches are a longer-term, more attractive solution. The real crux of the debate is how soon we can get either approach commercialized, and we look forward to hearing both speakers’ thoughts on realistic timelines.
  • (1:10 pm – 2:40 pm) Clinical 4: Debate: Is There a Role for Blinded CGM in Addition to Real Time CGM? Dr. Steve Edelman (UCSD, San Diego, CA) will take the “no” position, while Dr. Ian Blumer (University of Toronto, Ontario, Canada) will take the “yes” position. Like the biology vs. mechanical debate, we see this as an “and” story. For patients who are willing and able to wear it, unblinded real-time CGM brings tremendous diabetes and behavior change advantages. Still, blinded CGM is a great option for periodic diagnostic use, especially if the design is smaller, cheaper, and lower hassle than traditional CGM. Abbott is certainly investing in blinded CGM with FreeStyle Libre Pro in India and potentially coming next year in the US (under FDA review); Medtronic has long been in this business with the iPro franchise. Blinded CGM is clearly not as great as real-time CGM, but this is a false choice – the real comparison is periodic blinded CGM vs. isolated SMBG values that miss 99.9% of glucose fluctuations.  
  • (2:55 pm – 4:45 pm) Scientific 5: Artificial Pancreas: What is Needed? This sure-to-be-packed session features a star-studded lineup to discuss the biggest needs in closed-loop development: Better algorithms? Better CGM? Glucagon? All three topics will get their fair share of airtime from Drs. Claudio Cobelli (Padova), Harvard’s Garry Steil, and McGill’s Ahmad Haidar, respectively. Dr. Moshe Phillip (Schneider Children’s Medical Center of Israel, Tel-Aviv, Israel) will follow by discussing perhaps the biggest and most challenging need of all: “commercializing actual products.” [As a reminder, Medtronic licensed the DREAM MD-Logic algorithm in April for future closed-loop systems after the 670G.] Algorithm expert Dr. Eyal Dassau (now at Harvard following Dr. Frank Doyle’s appointment as Dean of the Engineering school) will address the challenges of using model-based control algorithms. We see current technology as outstanding in the overnight setting, and good enough during the day to help many patients (e.g., those who forget to bolus). To get to fully automated systems – the goal of many academics – it will really require faster insulin and the addition of other hormones (glucagon, amylin).
  • (3:05 pm – 4:40 pm) Clinical 5: Developments in Insulin Pump Therapy. The highly respected Dr. John Pickup (King’s College London, UK) will provide a very practically focused lecture on the optimal use of insulin pumps, setting the stage for Dr. Stuart Weinzimer (Yale University School of Medicine, New Haven, CT) to discuss whether new insulins or insulin pumps will dominate the future type 1 market. Now that is a fascinating question – how will Tresiba and Toujeo stack up to hybrid closed loop? Will SGLT-2 inhibitors for type 1 (if approved) make MDI more compelling, since they could eliminate much of the bolus convenience advantage of pumps? Will smart insulin make it to market?

Saturday, October 24

  • (8:00 am – 9:45 am) Scientific 6: Novel Insulins. Dr. Matthew Webber of Boston Children’s Hospital will share how his group’s synthetic insulin formulations have demonstrated glucose-responsive activity in a mouse model of diabetes. We reported on this study earlier this year, and though the compound is still at a very early stage, we are intrigued to see progress from different groups on this long-awaited concept. Meanwhile, Dance BioPharm CEO Dr. John Patton will share the company’s approach to inhaled insulin. As a reminder, the company’s product, Dance 501, is designed to deliver a liquid recombinant human insulin formulation at mealtimes through a small handheld electronic inhaler. The company filed to go public last year, though subsequently withdrew their application due to the approval of MannKind’s Afrezza and feedback from the FDA. How does Afrezza’s slow commercial uptake impact Dance’s chances? The session will also include Dr. Andreas Pfützner on a novel topic: “Stability of Insulin and Global Warming.” We know that at least Thermalin is working on heat stable insulin (preclinical), and presumably others are too.  
  • (8:00 am – 9:45 am) Clinical 6: Nutrition and the Microbiome. How can we alter the microbiome to treat diabetes? The research is still early, and hopefully this session’s speaker Dr. Frank Greenway (Louisiana State University, LA) can shed some light on the topic. ADA and JDRF just published their summary on the state of the field, and there are plenty of remaining questions to answer.  The session also includes UCSD’s Dr. Amir Zarrinpar on whether meal timing can protect against “diabesity,” and Dr. Osama Hamdy on “The Diabetes Breakthrough for Successful Weight Loss.”
  • (10:10 am – 11:45 am) Scientific 7: Importance of Hypoglycemia as an Endpoint in Clinical Trials. We can hardly wait for this panel discussion … just look at the names: JDRF’s Dr. Aaron Kowalski, Abbott’s Dr. Timothy Dunn, UVA’s Dr. Boris Kovatchev, Kinexum’s Dr. Alexander Fleming (formerly of FDA), and King’s College veteran Dr. John Pickup. The question of course is not whether hypoglycemia should be considered (that’s a given!) but how to facilitate its incorporation into clinical trials. How should hypoglycemia be defined? Should it be a co-primary endpoint with A1c? Can we get payers to accept moderate hypoglycemia as a valid endpoint? Can we incentivize big pharma to employ CGM or FreeStyle Libre consistently?
  • (10:10 am – 11:45 am) Clinical 7: The Social Media Phenomenon. DTM has done a commendable job of including social media in past meetings, and it’s great to see a whole session on the topic this year. The three presentations will take a healthcare provider view, including “The Reluctant Tweet(er)” (Dr. Pratik Choudhary), preventing online bullying (Kevin McMahon), and social media for physicians (Dr. Patricia Salber). We are glad to see social media gaining mainstream provider acceptance, and now the focus is on providing hands-on support and sharing best practices (similar to AADE). We hope to hear what proportion of attendees is already on social media.
  • (12:45 pm – 2:00 pm) Scientific 8: Mobile Apps. Standout presenter in this session is the FDA’s highly respected, pragmatic Mr. Bakul Patel, the Agency’s Associate Director for Digital Health – he was the main author of the mobile medical apps and MDDS draft guidances, and has emphasized the Agency’s goal to take a hands-off approach to certain digital health devices. We look forward to hearing his perspective on diabetes, which certainly includes both low and high-risk digital devices (e.g., retrospective CGM data vs. closed-loop systems). Stanford’s Dr. Rajiv Kumar will precede Mr. Patel, discussing the utility of linking CGM data with electronic health records – we assume this is the pilot project with Dexcom and EPIC we first heard about at EASD.
  • (12:45 pm – 2:30 pm) Clinical 8: What’s Next in Diabetic Limb Salvage and Prevention. We’re very glad to see attention to this topic, which does not get a lot of airtime at diabetes tech conferences. Talks will address activity (Dr. Bijan Najafi), new technology for treating diabetic foot disease (Dr. Stephen Twigg), and pain from neuropathy (Dr. Rodica Pop-Busui). 
  • (2:25 pm – 4:35 pm) Scientific 9: New Developments in CGM. This session should make for an outstanding finish to DTM 2015. We will hear about new CGM technology from:
    • Medtronic – Dr. Rajiv Shah (Medtronic, Northridge, CA) will provide an update on the company's CGM pipeline following last week’s US launch of the MiniMed Connect device for smartphone viewing and remote monitoring of pump/CGM data (MiniMed 530G, Revel). The Connect is presumably a step toward Medtronic launching its own Bluetooth transmitter (Guardian Mobile), and we hope to hear an update on that product’s FDA submission timing. In terms of new sensors, Enlite 3 is in a pivotal study with the MiniMed 640G (FDA submission expected this calendar year), and we saw data from Medtronic’s next-gen Harmony CGM sensor at ATTD 2015 (MARD of 9% vs. YSI in a small (n=15) seven-day study). We also wonder if Medtronic’s orthogonally redundant CGM (glucose oxidase + optical sensing) is still in the works; the first in-human data was presented at ATTD 2014, though the incremental advantage was small.
    • Roche – At Roche’s 2Q15 Analyst Event, COO Mr. Roland Diggelman shared its novel CGM was “coming to the market in the next 18 months.” This was the most concrete timeline we had heard to date, and it’s encouraging to hear that the company is pushing forward in an increasingly competitive market segment. This update from Dr. Guenther Schmelzeisen-Rekeker will hopefully share more on the accuracy, calibration frequency, on-body size, and connectivity.
    • Abbott – The EU market introduction of FreeStyle Libre has been impressive, and we hope to hear an update on the US launch timeline from Mr. Scott Harper. As a reminder, the blinded FreeStyle Libre Pro is under FDA review, though there is no public timeline on an FDA submission of the unblinded consumer version.
    • Senseonics – Senseonics submitted its implanted CGM to an EU Notified Body earlier this year and is optimistic that a CE Mark will come by late fall. As we noted in August, Senseonics plans to launch in Sweden and Norway by the end of 2015. The company has completed its EU pivotal trial to support the filing and 90-day data has been encouraging – MARD in a subset of patients (n=44) was 11.4% vs. YSI. More detailed data from this trial should come in this presentation from Dr. Jort Kropff (University of Amsterdam, Netherlands). The posting has not been updated.
    • Dexcom – This presentation will focus on the newly launched G5 mobile CGM, though we hope for an update on all facets of the company’s pipeline: an insulin dosing claim; the Google partnership; pump integrations with Tandem, Insulet, and Animas; new data on the G6 sensor; and beyond. Dexcom announced EU approval of the G5 mobile system at EASD and will have begun its launch by the time DTM begins (in tandem with the US launch). Dexcom’s Senior Director of R&D Apurv Kamath is not someone we hear from often, as VP of R&D Jake Leach normally gives these talks.
    • Arkray – We first learned that Arkray was developing a 14-day CGM at DTM 2014. Mr. Shinjiro Sekimoto returns again this year to discuss the company’s novel glucose sensing technology that employs Direct Electron Transfer (DiET) technology. Preliminary findings were encouraging, though we are hopeful Mr. Sekimoto’s 2015 presentation will feature a more comprehensive dive than last year’s, addressing: (i) sensor performance in the hypo- and hyperglycemic ranges; (ii) studies in people with diabetes; and (iii) calibration scheme details.
    • GlySens – GlySens announced earlier this year an extended clinical trial of its second-gen implantable CGM from the originally approved six-month duration to the system’s commercially intended duration of twelve months. The accuracy, reliability, cost, and commercialization strategy remain question marks for the company, though we expect Dr. Joseph Lucisano’s presentation will answer some of these questions (hopefully sharing preliminary six-month data from the trial). With many companies moving quickly on next-gen products, it’s hard to know how the advantages of an implantable system will stack up against these increasingly strong competitive offerings (factory calibration, smartphone connectivity, smaller on-body components).
  • (2:55 pm – 4:40 pm) Clinical 9: SMBG and Bolus Calculators. This clinical session will discuss the benefits and limitations of SMBG, including a lecture from Dr. Timothy Bailey (AMCR Institute, Escondido, CA). It is tough to go head-to-head with the parallel CGM session!
  • (4:40 pm – 5:00 pm) Scientific and Clinical 10: Live Demonstrations. As is typical, DTM 2015 will close with live product demonstrations. Organizers have not yet announced who will present, though the session always seems to draw audible gasps from attendees seeing new technology (e.g., FreeStyle Libre in 2014) for the first time.


-- by Ava Runge, Varun Iyengar, Adam Brown, and Kelly Close